1. Home
  2. SRG vs BMEA Comparison

SRG vs BMEA Comparison

Compare SRG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seritage Growth Properties

SRG

Seritage Growth Properties

HOLD

Current Price

$1.58

Market Cap

102.5M

Sector

Real Estate

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

BUY

Current Price

$0.84

Market Cap

92.1M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
SRG
BMEA
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.5M
92.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SRG
BMEA
Price
$1.58
$0.84
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $6.57
AVG Volume (30 Days)
135.0K
★ 2.3M
Earning Date
11-13-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
53.90
★ 69.19
EPS
N/A
★ N/A
Revenue
★ $18,204,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 3.30
N/A
52 Week Low
$1.55
$0.80
52 Week High
$4.38
$2.24

Technical Indicators

Market Signals
Indicator
SRG
BMEA
Relative Strength Index (RSI) 34.21 27.90
Support Level $1.57 N/A
Resistance Level $2.08 $1.47
Average True Range (ATR) 0.08 0.10
MACD 0.01 -0.05
Stochastic Oscillator 14.52 7.83

Price Performance

Historical Comparison
SRG
BMEA

About SRG Seritage Growth Properties

Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: